MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-06-30.

Cash Flow Overview

Free Cash flow
-$172,234K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-06-30
Stock-based compensation
14,531
Net loss
-182,779
Other
0
Noncash operating lease expense
316
Prepaid expenses and other assets
4,202
Other noncurrent liabilities
877
Operating lease liabilities
-354
Accrued expenses
4,150
Accounts payable
-752
Change in fair value of warrant liability
-516
Depreciation
18
Amortization of debt discount and accretion of deferred debt costs
773
Net accretion of discounts on investments in marketable securities
4,224
Net cash used in operating activities
-172,162
Proceeds from sales and maturities of marketable securities
212,131
Purchases of property and equipment
72
Purchases of marketable securities
326,514
Net cash used in investing activities
-114,455
Proceeds from issuance of common stock upon exercise of common stock warrants
0
Proceeds from issuance of common stock under employee stock purchase plan
263
Proceeds from issuance of common stock upon exercise of stock options
59
Payments for taxes related to net share settlement upon vesting of restricted stock units
1,598
Payments of deferred offering costs
0
Proceeds from issuance of common stock under at-the-market program, net of issuance costs
21,006
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of issuance costs
269,903
Net cash provided by financing activities
289,633
Net change in cash and cash equivalents
3,016
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

89bio, Inc. (ETNB)

89bio, Inc. (ETNB)